254 related articles for article (PubMed ID: 19002686)
1. The combined evaluation of interim contrast-enhanced computerized tomography (CT) and FDG-PET/CT predicts the clinical outcomes and may impact on the therapeutic plans in patients with aggressive non-Hodgkin's lymphoma.
Yang DH; Min JJ; Jeong YY; Ahn JS; Kim YK; Cho SH; Chung IJ; Bom HS; Kim HJ; Lee JJ
Ann Hematol; 2009 May; 88(5):425-32. PubMed ID: 19002686
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic evaluation and prognostic value of interim hybrid PET/CT with (18)F-FDG after three to four cycles of chemotherapy in non-Hodgkin's lymphoma.
Zhao J; Qiao W; Wang C; Wang T; Xing Y
Hematology; 2007 Oct; 12(5):423-30. PubMed ID: 17852456
[TBL] [Abstract][Full Text] [Related]
3. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography.
Juweid ME; Wiseman GA; Vose JM; Ritchie JM; Menda Y; Wooldridge JE; Mottaghy FM; Rohren EM; Blumstein NM; Stolpen A; Link BK; Reske SN; Graham MM; Cheson BD
J Clin Oncol; 2005 Jul; 23(21):4652-61. PubMed ID: 15837965
[TBL] [Abstract][Full Text] [Related]
4. Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma.
Cremerius U; Fabry U; Wildberger JE; Zimny M; Reinartz P; Nowak B; Schaefer W; Buell U; Osieka R
Bone Marrow Transplant; 2002 Jul; 30(2):103-11. PubMed ID: 12132049
[TBL] [Abstract][Full Text] [Related]
5. 18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's Lymphoma-comparison with CT.
Mikhaeel NG; Timothy AR; O'Doherty MJ; Hain S; Maisey MN
Leuk Lymphoma; 2000 Nov; 39(5-6):543-53. PubMed ID: 11342337
[TBL] [Abstract][Full Text] [Related]
6. FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease.
Querellou S; Valette F; Bodet-Milin C; Oudoux A; Carlier T; Harousseau JL; Chatal JF; Couturier O
Ann Hematol; 2006 Nov; 85(11):759-67. PubMed ID: 16871391
[TBL] [Abstract][Full Text] [Related]
7. Early determination of prognosis by interim 3'-deoxy-3'-18F-fluorothymidine PET in patients with non-Hodgkin lymphoma.
Lee H; Kim SK; Kim YI; Kim TS; Kang SH; Park WS; Yun T; Eom HS
J Nucl Med; 2014 Feb; 55(2):216-22. PubMed ID: 24365650
[TBL] [Abstract][Full Text] [Related]
8. Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: when do we really need FDG-PET?
Reinhardt MJ; Herkel C; Altehoefer C; Finke J; Moser E
Ann Oncol; 2005 Sep; 16(9):1524-9. PubMed ID: 15946979
[TBL] [Abstract][Full Text] [Related]
9. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.
Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
Blood; 1999 Jul; 94(2):429-33. PubMed ID: 10397709
[TBL] [Abstract][Full Text] [Related]
10. Whole-body diffusion-weighted MRI and (18)F-FDG PET/CT can discriminate between different lymphoma subtypes.
Mosavi F; Wassberg C; Selling J; Molin D; Ahlström H
Clin Radiol; 2015 Nov; 70(11):1229-36. PubMed ID: 26208992
[TBL] [Abstract][Full Text] [Related]
11. CT-based texture analysis potentially provides prognostic information complementary to interim fdg-pet for patients with hodgkin's and aggressive non-hodgkin's lymphomas.
Ganeshan B; Miles KA; Babikir S; Shortman R; Afaq A; Ardeshna KM; Groves AM; Kayani I
Eur Radiol; 2017 Mar; 27(3):1012-1020. PubMed ID: 27380902
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.
Qiao W; Zhao J; Wang C; Wang T; Xing Y
Hematology; 2010 Feb; 15(1):21-7. PubMed ID: 20132658
[TBL] [Abstract][Full Text] [Related]
13. Pediatric nonlymphoblastic non-Hodgkin lymphoma: baseline, interim, and posttreatment PET/CT versus contrast-enhanced CT for evaluation--a prospective study.
Bakhshi S; Radhakrishnan V; Sharma P; Kumar R; Thulkar S; Vishnubhatla S; Dhawan D; Malhotra A
Radiology; 2012 Mar; 262(3):956-68. PubMed ID: 22357895
[TBL] [Abstract][Full Text] [Related]
14. Assessment of the prognostic capacity of pretreatment, interim, and post-therapy (18)F-FDG PET/CT in extranodal natural killer/T-cell lymphoma, nasal type.
Jiang C; Zhang X; Jiang M; Zou L; Su M; Kosik RO; Tian R
Ann Nucl Med; 2015 Jun; 29(5):442-51. PubMed ID: 25801633
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?
Spaepen K; Stroobants S; Dupont P; Van Steenweghen S; Thomas J; Vandenberghe P; Vanuytsel L; Bormans G; Balzarini J; De Wolf-Peeters C; Mortelmans L; Verhoef G
J Clin Oncol; 2001 Jan; 19(2):414-9. PubMed ID: 11208833
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of interim and posttherapy 18F-FDG PET/CT in patients with mature T-cell and natural killer cell lymphomas.
Li YJ; Li ZM; Xia XY; Huang HQ; Xia ZJ; Lin TY; Li S; Xia Y; Cai XY; Jiang WQ
J Nucl Med; 2013 Apr; 54(4):507-15. PubMed ID: 23397008
[TBL] [Abstract][Full Text] [Related]
17. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.
Becherer A; Mitterbauer M; Jaeger U; Kalhs P; Greinix HT; Karanikas G; Pötzi C; Raderer M; Dudczak R; Kletter K
Leukemia; 2002 Feb; 16(2):260-7. PubMed ID: 11840293
[TBL] [Abstract][Full Text] [Related]
18. Complete Metabolic Response on Interim
Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC
Oncologist; 2017 May; 22(5):526-534. PubMed ID: 28377466
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of interim FDG PET/CT in Hodgkin's lymphoma patients treated with interim response-adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteria.
Le Roux PY; Gastinne T; Le Gouill S; Nowak E; Bodet-Milin C; Querellou S; Mahe B; Dubruille V; Blin N; Salaun PY; Bodere-Kraeber F
Eur J Nucl Med Mol Imaging; 2011 Jun; 38(6):1064-71. PubMed ID: 21308370
[TBL] [Abstract][Full Text] [Related]
20. FDG PET in response evaluation of bulky masses in paediatric Hodgkin's lymphoma (HL) patients enrolled in the Italian AIEOP-LH2004 trial.
Lopci E; Mascarin M; Piccardo A; Castello A; Elia C; Guerra L; Borsatti E; Sala A; Todesco A; Zucchetta P; Farruggia P; Cistaro A; Buffardi S; Bertolini P; Bianchi M; Moleti ML; Bunkheila F; Indolfi P; Fagioli F; Garaventa A; Burnelli R;
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):97-106. PubMed ID: 30219963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
